Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates

Core Insights - Neurocrine Biosciences reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.58 per share, and showing an increase from $1.24 per share a year ago, resulting in an earnings surprise of +29.11% [1] - The company achieved revenues of $794.9 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.73% and up from $622.1 million year-over-year [2] - Neurocrine shares have increased approximately 9.1% year-to-date, while the S&P 500 has gained 16.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.71 on revenues of $785.17 million, and for the current fiscal year, it is $4.49 on revenues of $2.79 billion [7] - The estimate revisions trend for Neurocrine was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Neurocrine belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Amneal Pharmaceuticals, another company in the same industry, is expected to report quarterly earnings of $0.13 per share, reflecting a year-over-year decline of -18.8%, with revenues projected at $773.6 million, up 10.1% from the previous year [9][10]